The stimulant modafinil has proved to be an effective treatment modality for narcolepsy and related sleep disorders and is also being studied for use during sustained military operations to ameliorate the effects of fatigue due to sleep loss. However, a previous study reported that a relatively large, single dose of modafinil (300 mg), administered to already sleep-deprived individuals, caused participants to overestimate their cognitive abilities (i.e. 'overconfidence'). Because the predominant application of modafinil is in otherwise healthy, non-sleep-deprived individuals, the present study investigated the generality of modafinil-induced overconfidence in a group of 18 healthy, non sleep-deprived adults. The design involved a double-blind, placebo controlled, fully within-subjects manipulation of placebo and modafinil (4 mg/kg: approximately 300 mg, on average) over three 50-min cognitive testing sessions (i.e. before drug ingestion, and at 90 and 180 min after drug ingestion). The cognitive task battery included subjective assessments of mood, fatigue, affect, vigor and motivation, and cognitive assessments of serial reaction time, logical reasoning, visual comparison, mental addition and vigilance. In addition, trial-by-trial confidence judgements were obtained for two of the cognitive tasks and more global, task level assessments of performance were obtained for four of the cognitive tasks. Relative to placebo, modafinil improved fatigue levels, motivation, reaction time and vigilance. In terms of self-assessments of cognitive performance, both the placebo and modafinil conditions were 'well calibrated' on trial-by-trial confidence judgements, showing neither marked over- nor under-confidence. Of note, the modafinil condition displayed a non-significant tendency towards 'overconfidence' for task-level assessments of performance. The present findings highlight the need for continued research on the many complex interactions involving fatigue states, occasional versus long-term stimulant use, and subjective assessments of fatigue and cognitive performance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hup.596 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The observation of seasonal variation of fatigue in multiple sclerosis depends on the measurement instrument.
Mult Scler Relat Disord
December 2024
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA. Electronic address:
Article Synopsis
- The study investigates how seasonal temperature changes affect fatigue levels in multiple sclerosis (MS) patients, a common symptom of the disease.
- Fatigue was assessed using two different measurement tools: the Modified Fatigue Impact Scale (MFIS) and the Neuro-QoL fatigue score, with the results showing that MFIS scores were influenced by season and location, while Neuro-QoL scores were not.
- The findings suggest that the effect of temperature on MS-related fatigue varies based on the specific measurement tool used.
Efficacy of oral modafinil on accelerating consciousness recovery in adult patients with moderate to severe acute traumatic brain injury admitted to intensive care unit: a randomized double-blind clinical trial.
Neurosurg Rev
December 2024
Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Chamran Blvd, Shiraz, 7194815711, Iran.
Background: Traumatic Brain Injury (TBI) is a leading cause of hospitalization and disability in young and middle-aged adults. This study aims to survey the efficacy of oral modafinil, a low-side-effect central nervous system stimulant, in the enhancement of consciousness recovery in moderate to severe TBI patients in the ICUs of a referral trauma center.
Materials And Methods: All ICU patients meeting inclusion criteria between April 2021 and April 2023 were screened.
Residual hypersomnia in unipolar and bipolar depression: A systematic review.
World J Biol Psychiatry
December 2024
Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Article Synopsis
- - The study aims to address the ongoing symptoms of depression, particularly focusing on residual hypersomnia, which significantly impacts daily life and is under-researched.
- - A systematic review analyzed data from multiple databases to assess the prevalence and treatment options for residual hypersomnia in depression, finding that current treatments, including modafinil and CPAP for patients with sleep apnea, show limited long-term effectiveness.
- - The research highlights challenges like unclear definitions and a lack of rigorous trials, emphasizing the need for more studies to improve the understanding and management of residual hypersomnia in depressed patients.
Modulation of cerebellar-cortical connectivity induced by modafinil and its relationship with receptor and transporter expression.
Biol Psychiatry Cogn Neurosci Neuroimaging
November 2024
Department of Neuroscience, Imaging, and Clinical Sciences, University "G. d'Annunzio" of Chieti-Pescara, Italy; Institute for Advanced Biomedical Technologies (ITAB), "G. d'Annunzio" University, Chieti-Pescara, Italy; Molecular Neurology Unit, Center for Advanced Studies and Technology (CAST), University "G. d'Annunzio" of Chieti-Pescara, Italy. Electronic address:
Article Synopsis
- - Modafinil is used to treat narcolepsy and as a cognitive enhancer, impacting the connectivity of brain networks related to attention and executive function, with less known about its effects on subcortical areas.
- - In a study with 50 participants, researchers measured resting-state fMRI connectivity before and after a single dose of modafinil or a placebo, focusing on cerebellar-neocortical relationships and neurotransmitter receptor expression.
- - Results showed that modafinil enhanced connectivity in specific cerebellar regions (Crus I and Vermis IX) with prefrontal areas and other brain regions, linking these changes to the presence of dopaminergic and histaminergic receptors.
Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.
Cochrane Database Syst Rev
November 2024
Departement de Biostatistique et Informatique Médicale, Hôpital Saint Louis, 75475 Paris, France.
Article Synopsis
- Excessive daytime sleepiness is a frequent issue in myotonic dystrophy, prompting the use of psychostimulants to treat hypersomnia in these patients.
- The study aimed to evaluate the effectiveness of psychostimulants in alleviating hypersomnia symptoms in individuals with myotonic dystrophy, using data from randomized controlled trials.
- A total of six trials involving 136 adult participants were reviewed, suggesting a positive short-term impact of psychostimulants on improving wakefulness, with most trials showing low risk of bias.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!